BIOMARKERS OF THERAPEUTIC RESPONSE AND DISEASE PROGNOSIS IN NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

The search for biomarkers of juvenile idiopathic arthritis (JIA) is a promising and rapidly expanding area of research. The identified biomarkers can help analyze the clinical heterogeneity of the disease, measure disease activity parameters, predict clinical remission, relapse, drug response, time course, complications, and prevent disease exacerbations. Modern generation of molecular and cellular biomarkers (autoantibodies, acute phase inflammatory proteins, cytokines, chemokines, vascular endothelial activation markers, immunoglobulins, components of the complement system, lymphocyte subpopulations, metabolic products of bone and cartilage tissue, intracellular signaling molecules, proteases, genetic, epigenetic, transcriptome markers) is an important tool for prevention, early diagnosis, assessment of activity, progression rate, clinical and laboratory subtypes of JIA, predicting the effectiveness of therapy and the risk of developing adverse reactions during treatment. Deciphering the key pathogenetic mechanisms of JIA has made it possible to identify molecular and cellular biomarkers that can be used as therapeutic targets. Incorporating valid and reliable biomarkers into standard clinical care can help develop more effective patient-tailored treatment regimens and improve therapeutic strategies. Establishing biomarkers that predict the risk of exacerbation of the disease may lead to the determination of the optimal ways to stop treatment after achieving clinical remission.